US scientists vow to answer CRISPR’s sticky moral questions
Top science academics have launched an initiative to consider emerging human gene-editing tools such as CRISPR-Cas9.
Top science academics have launched an initiative to consider emerging human gene-editing tools such as CRISPR-Cas9.
In a House bill that largely mirrors one reintroduced earlier this year in the Senate, CROs (contract research organizations) would be able to capture a share of the R&D tax credit, thereby making the US more competitive with other countries that offer...
A consortium including WuXi PharmaTech has agreed to acquire biotech client Ambrx for its antibody-drug conjugate (ADC) conjugation technology.
inVentiv Health has expanded its compliance products and services to assist biopharma companies conducting non-interventional studies (NIS).